- Page 1 and 2:
A systematic review and economic mo
- Page 3 and 4:
A systematic review and economic mo
- Page 5 and 6:
Objectives: To assess the clinical
- Page 7 and 8:
Glossary and list of abbreviations
- Page 9 and 10:
Glossary Adverse effect An abnormal
- Page 11 and 12:
Glossary continued effects. Sometim
- Page 13 and 14:
Glossary continued point between tw
- Page 15 and 16:
Background Attention deficit hypera
- Page 17 and 18:
mean differences with 95% confidenc
- Page 19:
This review examines the clinical a
- Page 22 and 23:
4 Background E. Symptoms should not
- Page 24 and 25:
6 Background Concerta XL Concerta X
- Page 26 and 27:
8 Methods for reviewing effectivene
- Page 28 and 29: 10 Methods for reviewing effectiven
- Page 31 and 32: Quantity and quality of research av
- Page 33 and 34: TABLE 1 The quality of included stu
- Page 35 and 36: TABLE 2 An overview of trials inclu
- Page 37 and 38: TABLE 2 An overview of trials inclu
- Page 39 and 40: TABLE 3 MPH low dose (≤15 mg/day)
- Page 41 and 42: Quality of life Only one of the 12
- Page 43 and 44: TABLE 5 MPH medium dose (15-30 mg/d
- Page 45 and 46: Hyperactivity All nine studies that
- Page 47 and 48: TABLE 6 Results for hyperactivity [
- Page 49 and 50: Study Parallel trials Buitelaar 199
- Page 51 and 52: TABLE 8 Results for hyperactivity [
- Page 53 and 54: Study Parallel trials Gittelman-Kle
- Page 55 and 56: TABLE 11 MPH high dose (>30 mg/day)
- Page 57 and 58: TABLE 14 ER-MPH medium dose (20-40
- Page 59 and 60: Study Crossover trials Stein 2003 S
- Page 61 and 62: TABLE 19 Results for hyperactivity
- Page 63 and 64: TABLE 22 MPH low dose (≤ 15 mg/da
- Page 65 and 66: TABLE 24 MPH medium dose (15-30 mg/
- Page 67 and 68: assessed by parents and teachers. I
- Page 69 and 70: TABLE 27 Results for hyperactivity
- Page 71 and 72: TABLE 30 DEX medium dose (10-20 mg/
- Page 73 and 74: TABLE 33 Results for hyperactivity
- Page 75 and 76: TABLE 38 DEX medium dose (10-20 mg/
- Page 77: TABLE 41 DEX-SR plus non-drug inter
- Page 81 and 82: Hyperactivity Five trials (publishe
- Page 83 and 84: TABLE 47 IR-MPH low-dose (≤ 15 mg
- Page 85 and 86: STP. 77,78 Neither examined hyperac
- Page 87 and 88: Adverse events No significant diffe
- Page 89 and 90: did report that there were no signi
- Page 91 and 92: Summary The one study in this categ
- Page 93 and 94: showed persisting significant super
- Page 95 and 96: easily rectified with dosage adjust
- Page 97 and 98: Aim The aim of this chapter is to r
- Page 99 and 100: only level of social disability tha
- Page 101 and 102: did not include a ‘global’ HRQo
- Page 103 and 104: might decrease but costs would be e
- Page 105 and 106: 1st line pharmacotherapy Response,
- Page 107 and 108: TABLE 70 Data for weighted average
- Page 109 and 110: The probabilistic results were used
- Page 111 and 112: The review also uncovered a mis-ref
- Page 113 and 114: TABLE 77 Results of sensitivity ana
- Page 115 and 116: TABLE 80 Response a rates (%) estim
- Page 117 and 118: TABLE 82 Drug costs used in the cos
- Page 119 and 120: The review of the economic evidence
- Page 121 and 122: Extrapolation A secondary analysis
- Page 123 and 124: economic model rests on the assumpt
- Page 125 and 126: TABLE 87 Data used in calculating w
- Page 127 and 128: not fully probabilistic. The averag
- Page 129 and 130:
Probability cost-effective 1.0 0.9
- Page 131 and 132:
TABLE 93 Results of sensitivity ana
- Page 133 and 134:
Base case model Responder to MPH Re
- Page 135 and 136:
TABLE 96 Results of the sensitivity
- Page 137 and 138:
The same method for synthesising th
- Page 139 and 140:
TABLE 103 Results of the economic m
- Page 141:
of the 64 identified in the clinica
- Page 144 and 145:
126 Discussion impact of active dru
- Page 147:
MPH, DEX and ATX improve hyperactiv
- Page 151 and 152:
1. National Institute for Clinical
- Page 153 and 154:
tutoring on the behavior and achiev
- Page 155 and 156:
91. Stein MA, Blondis TA, Schnitzle
- Page 157 and 158:
140. Hill P, Taylor E. An auditable
- Page 159 and 160:
189. Francis S, Fine J, Tannock R.
- Page 161 and 162:
235. Rhodes SM, Coghill DR, Matthew
- Page 163 and 164:
hyperactive boys: comparative and c
- Page 165 and 166:
This version of HTA monograph volum
- Page 167 and 168:
380 Health Technology Assessment Pr
- Page 169:
382 Health Technology Assessment Pr